Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 62, Issue 2, Pages -Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.01576-17
Keywords
Acinetobacter baumannii; ETX2514; antibiotic resistance; beta-lactamase inhibitor; sulbactam
Categories
Funding
- AstraZeneca
- Entasis Therapeutics
Ask authors/readers for more resources
The novel diazabicyclooctenone ETX2514 is a potent, broad- spectrum serine beta-lactamase inhibitor that restores sulbactam activity against resistant Acinetobacter baumannii. The frequency of spontaneous resistance to sulbactam- ETX2514 in clinical isolates was found to be 7.6 x 10(-10) to < 9.0 x 10(-10) at 4 x MIC and mapped to residues near the active site of penicillin binding protein 3 (PBP3). Purified mutant PBP3 proteins demonstrated reduced affinity for sulbactam. In a sulbactam-sensitive isolate, resistance also mapped to stringent response genes associated with resistance to PBP2 inhibitors, suggesting that in addition to beta-lactamase inhibition, ETX2514 may enhance sulbactam activity in A. baumannii via inhibition of PBP2.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available